Patient enrollment underway in Phase 1/2 clinical trial in patients with advanced gastrointestinal stromal tumors (GIST)
Nomination of development candidate for fourth-generation epidermal growth factor receptor (EGFR) program targeting non-small cell lung cancer (NSCLC) expected in Q3 2022; IND expected in 2023
Continue to advance additional preclinical programs with one or more targets expected to be nominated in 2022
$244.7 million in cash and cash equivalents, expected to fund operations into the second half of 2024
https://finance.yahoo.com/news/theseus-pharmaceuticals-announces-business-highlights-120000211.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.